FQ
LAB icon

First Quadrant’s Standard BioTools LAB Stock Holding History

First Quadrant’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-32,675
Closed -$403K – 634
2019
Q2 		$403K Buy
32,675
+6,563
+25% +$83.6K 0.03% 436
2019
Q1 		$347K Buy
+26,112
New +$275K 0.03% 412

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

First Quadrant's LAB Position: Q3 2019 in Review

First Quadrant sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 32,675 shares — an estimated $403K sold.

First Quadrant first reported a position in LAB in Q1 2019 and held it in 2 quarters. The position peaked at $403K in Q2 2019. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

  • First Quadrant reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
  • First Quadrant sold 32,675 Standard BioTools shares in Q3 2019, an estimated $403K.
  • First Quadrant first reported a position in Standard BioTools in Q1 2019 and held it in 2 quarters.
  • First Quadrant's Standard BioTools position peaked at $403K in Q2 2019.
  • 125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on First Quadrant's 13F filing for Q3 2019, filed 25 Oct 2019.